

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,568-Conf. #3949
				Filing Date	July 11, 2003
				First Named Inventor	Kai W. Wucherpennig
				Art Unit	1644
				Examiner Name	M. N. Dibrino
Sheet	1	of	2	Attorney Docket Number	DFS-044.01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
	BA	WO-01/70245	09-27-2001			√

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Altman et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," Science, 274(5284):94-96 (1996)	
	CB	Bikoff et al., "Distinct Peptide Loading Pathways for MHC Class II Molecules Associated with Alternative Ii Chain Isoforms," Journal of Immunology, 160(7):3101-3110 (1998)	
	CC	Busch et al., "Accessory molecules for MHC class II peptide loading," Current Opinion in Immunology, 160(7):3101-3110 (1998)	
	CD	Busch et al., "Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers," Journal of Immunological Methods, 263(1-2):111-121 (2002)	
	CE	Crawford et al., "Detection of Antigen-Specific T Cells with Multivalent Soluble Class II MHC Covalent Peptide Complexes," Immunity, 8(6):675-682 (1998)	
	CF	Cunliffe et al., "Optimization of peptide linker length in production of MHC class II/peptide tetrameric complexes increases yield and stability, and allows identification of antigen-specific CD4+ T cells in peripheral blood mononuclear cells," European Journal of Immunology, 32(12):3366-3375 (2002)	
	CG	Day et al., "Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers," The Journal of Clinical Investigation, 112(6):831-842 (2003)	
	CH	Gauthier et al., "Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein," Proceedings of the National Academy of Sciences USA, 95(1):11828-11833 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/617,568-Conf. #3949
				Filing Date	July 11, 2003
				First Named Inventor	Kai W. Wucherpennig
				Art Unit	1644
				Examiner Name	M. N. Dibrino
Sheet	2	of	2	Attorney Docket Number	DFS-044.01

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CI	Jensen et al., "Peptide exchange in MHC molecules," Immunological Reviews, 172:229-238 (1999)		
	CJ	Kozono et al., "Production of soluble MHC class II proteins with covalently bound single peptides," Nature, 369(6476):151-154 (1994)		
	CK	Kropshofer et al., "Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding," Proceedings of the National Academy of Sciences USA, 92(18):8313-8317 (1995)		
	CL	Meyer et al., "Direct enumeration of <i>Borrelia</i> -reactive CD4 T cells <i>ex vivo</i> by using MHC class II tetramers," Proceedings of the Academy of Sciences USA, 97(21):11433-11438 (2000)		
	CM	Zhu et al., "A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity <i>in vitro</i> and reduced affinity for bacterial superantigens," Eur. J. Immunol., 27(8):1933-1941 (1997)		
	CN	Supplementary European Search Report from EP 03 75 5725 (DFS-044.80) dated 1/13/09		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.